Stereotactic Ablative Radiotherapy for Oligometastatic Renal Cell Carcinoma
Posted: Wednesday, September 11, 2019
In patients with oligometastatic renal cell carcinoma, stereotactic ablative radiotherapy may be used to provide longitudinal disease control without the need for systemic therapy for more than 1 year. Yuanyuan Zhang, MD, PhD, of The University of Texas Southwestern in Dallas, and colleagues published their retrospective study establishing the safety and efficacy of this therapy in the International Journal of Radiation Oncology • Biology • Physics.
“Stereotactic ablative radiotherapy is a reasonable approach for select patients with oligometastatic renal cell carcinoma, offering excellent local control and potentially preserving quality of life without impacting future systemic therapy,” concluded the authors.
The team identified 47 patients with oligometastatic renal cell carcinoma who had been treated with front-line stereotactic ablative radiotherapy with a curative intent from 2007 to 2017 at The University of Texas Southwestern Kidney Cancer Program. Information regarding local control rates, toxicity, freedom from systemic therapy, overall survival, and first-line systemic therapy was collected for each patient.
In this cohort, the local control rate was 91.5% at 2 years, and there were no reported grade 3 or higher toxicities. The median freedom from systemic therapy after the first stereotactic ablative radiotherapy treatment was 15.2 months, at a median follow-up of 30 months. Patients who had metachronous disease saw improved freedom from systemic therapy (hazard ratio = 2.67), as did patients with solitary metastasis (hazard ratio = 2.26) and nonbone metastasis (hazard ratio = 2.21). Common systemic therapies initiated after stereotactic ablative radiotherapy were pazopanib (60.7%) and sunitinib (14.3%). The overall survival rates 1 and 2 years after stereotactic ablative radiotherapy were 93.1% and 84.8%, respectively.
Disclosure: The study authors reported no conflicts of interest.